Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Los Angeles, California

This page shows live ClinicalTrials.gov search results for Los Angeles, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
4635
Shown on this page
12
Current sort
Recently updated
Location scope
Los Angeles, CA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Los Angeles, California. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 217–228 of 4,635 matching trials in Los Angeles, CA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Los Angeles

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

NCT04444921
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma
Interventions
Carboplatin, Nivolumab, Paclitaxel
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
579
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 381 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Recruiting Not applicable Interventional

Detecting and Monitoring Scoliosis Without Radiography: Standard Radiographic Monitoring Program Versus Self-Screening With Momentum SpineTM

NCT06825611
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Momentum Application
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Recruiting Phase 2 Interventional

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

NCT05593497
View directory record Official record
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
838
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
445
States / cities
Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Neurophysiologic Biomarkers in Rett Syndrome

NCT05932589
View directory record Official record
Conditions
Rett Syndrome, RTT, Rett Syndrome, Atypical
Interventions
EEG and Auditory and Visual Evoked Potentials (AEP and VEP), Clinical assessment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years · Female only
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Brookline, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
VX-147, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
10 Years to 65 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
223
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Active, not recruiting Phase 3 Interventional

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

NCT03712605
View directory record Official record
Conditions
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
Other · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
552
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Not yet recruiting Phase 3 Interventional

Cilostazol for Prevention of Recurrent Stroke Trial

NCT07174414
View directory record Official record
Conditions
Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions
Cilostazol 100 mg Tablets, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
52
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Active, not recruiting Phase 2 Interventional Results available

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT02311933
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
559
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST
Recruiting Phase 3 Interventional

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916
View directory record Official record
Conditions
Melanoma
Interventions
fianlimab, cemiplimab, relatlimab+nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
106
States / cities
Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 9:54 PM EST